A new breast cancer drug which extends women's lives by almost six months could be blocked from routine NHS access because it is too expensive, a health watchdog says.
Kadcyla, manufactured by Roche, can cost more than £90,000 per patient and is not effective enough to justify the price the NHS is being asked to pay, the National Institute for Health and Care Excellence (Nice) said.
The watchdog, which decides which new medicines are cost effective, said its guidance for the drug, also known as trastuzumab emtansine, was in draft form and is now up for public consultation.
If the recommendations are adopted, patients would have to apply to their local NHS and to the Cancer Drugs Fund (CDF) for the drug, a Nice spokeswoman said.
More top news
Five-year-old Yusuf Abdismad died from meningitis in January after a mix-up between emergency operators, it has emerged.
RAF Tornados will continue to carry out air strikes against so-called Islamic State into 2017, the Defence Secretary has announced.
A mother has paid an emotional tribute to the people who helped her find her missing three-year-old son after he went missing in Liverpool.